Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tibulizumab in adults with hidradenitis suppurativa
NCT06993610Phase 2Active, not recruiting
- Sponsor
- Zura Bio
- Start
- May 2025
- Primary completion
- Sep 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of tibulizumab in hidradenitis suppurativa (HS), sponsored by Zura Bio. Started May 2025; status: active, not recruiting.
02
Drugs
tibulizumab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT06993610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06993610.